S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

POINT Biopharma Global Stock Forecast, Price & News

-0.04 (-0.50 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume66,079 shs
Average Volume124,649 shs
Market Capitalization$718.27 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PNT News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

About POINT Biopharma Global

POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales





Market Cap
$718.27 million
Next Earnings Date
11/12/2021 (Estimated)
Not Optionable


Overall MarketRank

1.55 out of 5 stars

Medical Sector

1029th out of 1,361 stocks

Pharmaceutical Preparations Industry

499th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

POINT Biopharma Global (NASDAQ:PNT) Frequently Asked Questions

Is POINT Biopharma Global a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" POINT Biopharma Global stock.
View analyst ratings for POINT Biopharma Global
or view top-rated stocks.

What stocks does MarketBeat like better than POINT Biopharma Global?

Wall Street analysts have given POINT Biopharma Global a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but POINT Biopharma Global wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting POINT Biopharma Global?

POINT Biopharma Global saw a increase in short interest in September. As of September 30th, there was short interest totaling 1,280,000 shares, an increase of 52.7% from the September 15th total of 838,100 shares. Based on an average daily trading volume, of 168,300 shares, the short-interest ratio is currently 7.6 days. Currently, 1.8% of the shares of the stock are short sold.
View POINT Biopharma Global's Short Interest

When is POINT Biopharma Global's next earnings date?

POINT Biopharma Global is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for POINT Biopharma Global

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01.
View POINT Biopharma Global's earnings history

What price target have analysts set for PNT?

3 equities research analysts have issued 1-year price objectives for POINT Biopharma Global's shares. Their forecasts range from $8.00 to $17.00. On average, they expect POINT Biopharma Global's share price to reach $12.50 in the next year. This suggests a possible upside of 56.8% from the stock's current price.
View analysts' price targets for POINT Biopharma Global
or view top-rated stocks among Wall Street analysts.

What is POINT Biopharma Global's stock symbol?

POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT."

How do I buy shares of POINT Biopharma Global?

Shares of PNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is POINT Biopharma Global's stock price today?

One share of PNT stock can currently be purchased for approximately $7.97.

How much money does POINT Biopharma Global make?

POINT Biopharma Global has a market capitalization of $718.27 million.

What is POINT Biopharma Global's official website?

The official website for POINT Biopharma Global is www.pointbiopharma.com.

Where are POINT Biopharma Global's headquarters?

POINT Biopharma Global is headquartered at 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116.

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.